Boehringer Ingelheim, a Germany-based pharmaceutical company, is collaborating with Tsinghua University in Beijing to research and develop immunological therapies for infectious diseases, it was reported yesterday.

Scientists will work with immune modulation in the Boehringer Ingelheim-Tsinghua University Joint Research Centre for Immuno-Infection to combat infectious diseases.

This collaboration is an initiative of Boehringer Ingelheim's Research Beyond Borders and Cancer Immunology and Immune Modulation Research Departments.